Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

But rising Chinese import tariffs due to the trade war with the U.S. and longer-term concerns about costs or access are ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

M&A deals announced worldwide in July included a rail merger, which is the largest transaction in the past 12 months based on ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...